Evoke Pharma up 19% premarket on FDA acceptance of Gimoti refiling

The FDA has accepted for review Evoke Pharma’s (NASDAQ:EVOK) resubmitted marketing application for Gimoti (metoclopramide) nasal spray for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

The agency’s action date is June 19.

The company received a CRL in August 2019 citing pharmacology and quality issues.

Shares up 19% premarket on average volume.


Leave a Reply